Yang, Changyong

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 227

SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile

Wang, L.-M., Yang, C., Sun, X., Tian, Y., Zhang, J., Wang, X., Zhou, L., Wang, Z., Lin, Y., Wu, T., et al. (2025) · Molecular Cancer Therapeutics

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 2